BRAF and colorectal cancer: Our data suggests a predictive role for RNF43 mutation in response to encorafenib and cetuximab and when viewed in the context of other available data, suggests the utility of routine testing of RNF43 in patients with BRAF-mutated colorectal cancer, if external validation is supportive.